Short-Term Debt to Equity Ratio: CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO) utilizes bioinformatic IT systems for the computer-aided synthesis of anti-neurodegeneration agents, minimizing manual labor. Business development relies on patents and the success of clinical trials for Alzheimer's disease drugs, while the asset value tracked on the chart is 0.00. The company is developing unique treatments for Lewy body dementia, aiming to capture a market free of competition.
Metric breakdowns and analytics for cervomed.com (CRVO)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital CervoMed Inc.|CRVO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital CervoMed|CRVO - Company Cumulative Debt|Debt to Book Capitalization Ratio CervoMed, Inc.|CRVO - Company Long-Term Loans and Borrowings|Company Current Liabilities CervoMed|Quick Liquidity cervomed.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:CRVO CervoMed Inc
CervoMed Inc. (CRVO) development of dementia therapies requires significant expenditures, making the control of short-term liabilities relative to equity critical for maintaining liquidity. This ratio measures the company's reliance on short-term borrowing, allowing investors to assess the risk of resource shortages for clinical trials by analyzing the short-term debt to equity chart.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Short-Term Debt to Equity Amylyx AMLX|Ratio of Short-Term Indebtedness to Capital TRVI|PRAX: Short-Term Debt to Equity Ratio|AVXL: Short-Term Debt to Equity|CeriBell (CBLL) - Short-Term Debt to Equity|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Alector Inc.|Short-Term Debt to Equity Ratio Annexon Biosciences Inc. (ANNX)|Short-Term Debt to Capital OMER|NGNE - Current Liabilities to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|VYGR: Short-Term Debt to Capital Ratio|NMRA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|ACOG - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cognition Therapeutics, Inc.|Short-Term Debt to Capital Ratio IKT (Inhibikase Therapeutics Inc)|Short-Term Debt to Capital SAVA|Short-Term Debt to Equity Ratio assertiotx.com ASRT|Coya Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Short-Term Debt to Capital|Acumen Pharmaceuticals Inc. (ABOS) - Short-Term Debt to Equity Ratio|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|Clene - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio PEPG|Short-Term Debt to Equity JUNS|Short-Term Debt to Equity Relmada Therapeutics, Inc. (RLMD)|ANVS - Current Liabilities to Capital|Short-Term Debt to Equity Grace Therapeutics GRCE|AIFF: Short-Term Debt to Capital Ratio|ANEW Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Short-Term Debt to Equity Ratio|MetaVia (MTVA) - Short-Term Debt to Capital|Short-Term Debt to Equity NeurAxis, Inc|HSDT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|NEUP - Current Liabilities to Capital|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|ATHA - Short-Term Debt to Equity Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Current Liabilities to Capital Alzamend Neuro, Inc.|cyclerion.com (CYCN) - Short-Term Debt to Equity|Protagenic Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Equity CRGT|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI - Current Liabilities to Capital|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO - Short-Term Debt to Equity Ratio|Eliem - Short-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies|LBPH: Short-Term Debt to Capital|Short-Term Debt to Capital Ratio MRNS|Short-Term Debt to Equity Ratio NKGN|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Coefficient Synaptogenix Inc.|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL: Short-Term Debt to Capital Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|cerevel.com (CERE) - Short-Term Debt to Equity Ratio